This bill amends Minnesota Statutes 2024, section 256B.0625, subdivision 13g, to require the state's preferred drug list to ensure fair coverage of non-opioid drugs for the treatment or management of pain. It mandates that non-opioid drugs approved by the U.S. Food and Drug Administration (FDA) for pain management cannot be placed at a disadvantage compared to opioids in terms of preferred status or utilization management protocols such as prior authorization and step therapy. The bill also establishes transparency requirements for modifications to the preferred drug list, requiring public notice, comment opportunities, hearings, and documentation of public health impact assessments before making changes.